New FDA guidance signals a major shift for CAR-T development, calling for randomized trials with standard-of-care control groups and clear evidence of superiority over existing therapies, while ...

For traditional approval, CAR T therapies will need to establish superiority over current standard treatments, including ...

Restricted availability under an FDA-mandated drug safety program has limited the reach of CAR-T cell therapies for certain blood cancers—until now. The FDA has removed the Risk Evaluation and ...

While the use of radiation bridging therapy (BT) in chimeric antigen receptor (CAR) T-cell therapy for blood cancer is expanding, plenty of unanswered questions remain on topics such as ideal timing ...

CAR T-cell therapy, which transforms patients’ own immune cells into cancer-fighting warriors, has been extremely effective ...

For centuries, newer technologies have been met with initial hesitancy — the railroad, the telephone, and, more recently, the electric car. These transformative innovations were first introduced and ...

Chimeric antigen receptor (CAR)-T cells and T-cell therapies have been used in the treatment of various cancers for several years. In a review published in JAMA, a research team led by Christian ...

STEM-engineered CAR T cells performed as well as or better against cancer cells than did FDA-approved CAR T cells and kept their cancer-fighting abilities for longer.

The immune system is made up of different types of cells, which have different roles in protecting the body from infection. One type of immune cell called a B cell creates antibodies that attack ...